Nanochip Expected to raise hope for Prostate Cancer Patients28 June 2012
Prostate cancer is one of the major problems in men and a large number of men above 50 years of age are advised to check PSA annually to diagnose prostate cancer. The treatment options for the prostate cancer are also limited especially if the disease is in advance stage.
Researchers now suggest a new cancer therapy which uses silicon chip dubbed GEDI (Geometrically Enhanced Differential Immunocapture) and the device can actually identify and collect the cancer cells from patient’s bloodstream. Team of researchers from Weill Cornell Medical College, New York and Cornell’s College of Engineering, Ithaca has built the device.
The device captures the high concentration of rare cancer cells, which are specific to metastatic prostate cancer and the technique also helps in identifying the determination of efficacy of the current chemotherapy. The device provides the CTCs (Circulating Tumor Cells) and therefore helps in understanding the biology of metastasis and for developing new treatment and therapies for treating prostate cancer. The research findings have been published in the April issue of the journal PLos One.
Metastasis tells us about the spreading of cancer cells from prostate to other parts of bodies including liver and lung. These cancer cells pass through blood stream and damages the functions of other important organs and metastasis is the major cause of death among prostate cancer patients. The new device will help in identifying the metastasis stage and will also offer suitable treatment for the disease.
It will look like this: Nanochip Expected to raise hope for Prostate Cancer Patients